Should I buy MetLife (MET) stock or is it too late?
⭐ The most reliable of them, either direction: Piper Sandler — 71% of its targets hit on this sector (421 calls tested). It aims for $110 (+9.3 %), call made on September 23, 2026, maturing on September 23, 2027 (21 d ago).
Firm-by-firm track record on MetLife
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| UBS | 86 % | +25.4 % | 7 | $110 +9% |
| Morgan Stanley | 78 % | +18.5 % | 41 | $111 +10% |
| JP Morgan | 58 % | +12.8 % | 12 | $108 +7% |
| Wells Fargo | 64 % | +12.4 % | 22 | $110 +9% |
| Jefferies | 83 % | +11.7 % | 6 | $103 +2% |
| Piper Sandler | 50 % | +10.4 % | 8 | $110 +9% |
| Keefe, Bruyette & Woods | 75 % | +9.5 % | 12 | $108 +7% |
| Barclays | 63 % | +5.7 % | 19 | $111 +10% |
✅ Reasons to believe
- 91% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
- Median price target $110, i.e. +9% from the current price ($101).
- The most reliable firm on MET, UBS (86% hit rate, 7 scored calls), targets $110 (call made on October 6, 2026, maturing on October 6, 2027) (+9%) in its most recent call, and $95 (call made on November 6, 2025, maturing on November 6, 2026) (-6%) in the one coming due soonest.
- 8 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.6% yield), raised for 13 years — regular income on top of potential upside.
- Reasonable valuation (P/E ~19) relative to its sector.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 11 ratings, 1 is neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on MET
Median target $110 (+9%) · 11 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in MetLife now?
We won't decide for you. The facts: 91% of analysts rate it a buy, median target $110 (+9%), and UBS (most reliable on MET, 86%) targets $110. Weigh that against valuation (P/E ~19). This is not personalized advice.
Is it too late to invest in MetLife?
Not according to analysts: the median target ($110) is still +9% above the current price ($101) (most reliable on MET: UBS, 86%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is MetLife still worth investing in?
It depends on the gap between the price ($101) and its estimated value: analysts target $110 on median (+9%), with 91% buys (most reliable on MET: UBS, 86%). Cross-check with their real reliability on MET and the cautions above. Information, not advice.
What's the main risk in buying MET?
The consensus is not unanimous: of 11 ratings, 1 is neutral.
→ Go deeper: the full MetLife profile (consensus, analyst reliability, price target, performance).